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Abstract
Objective
To investigate the diagnostic value of serum neurofilament light chain (NFL) in patients with
clear signs of parkinsonism but whose specific diagnosis was yet uncertain.
Methods
Serum samples were collected from patients with clear signs of parkinsonism but with uncertain
diagnosis at the inclusion. Clinical diagnoses of Parkinson disease (PD) and atypical parkin-
sonism disorders (APDs) were established after 3 years of follow-up and updated again after
a maximum of 12 years in case longer follow-up data were available. Serum NFL was quantified
by singlemolecule array in patients with PD (n = 55) and APD (n = 29, multiple system atrophy =
22, progressive supranuclear palsy = 7) and 53 nonneurologic controls.
Results
Serum NFL levels were elevated and differentiated the APD group (mean 23.8 ± 10.3 ng/L)
from PD (mean 10.4 ± 4.9 ng/L) and controls (mean 11.5 ± 6.5 ng/L, p < 0.0001) with
accuracy levels up to 91% (sensitivity = 86% and specificity = 85%). Serum NFL strongly
correlated with CSFNFL levels (r = 0.72, p < 0.0001) in all groups and with age in PD (r = 0.78,
p < 0.0001) and controls (r = 0.66, p < 0.0001). In our cohort, the probability of having APD
was 76% (positive predictive value) and of having PD 92% (negative predictive value).
Conclusion
Serum NFL levels are markedly elevated in APD compared to PD and discriminate APDs from
PD with high accuracy. Serum NFL may be a useful clinical biomarker to identify APD, even at
stages when clinical symptoms are not yet conclusive.
Classification of evidence
This study provides Class II evidence that serum NFL levels accurately discriminate APDs
from PD.
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Parkinson disease (PD) is difficult to discriminate from the
various forms of atypical parkinsonism disorders (APDs),
such as multiple system atrophy (MSA), progressive supra-
nuclear palsy (PSP), and cortical basal syndrome (CBS), es-
pecially at early disease stages. The rate of misdiagnosis based
on clinical investigations alone can be as high as 15%, even in
the hands of experienced movement disorder specialists.1–3
Therefore, reliable biomarkers are needed for an accurate and
early differentiation between PD and APD.
Several proteins directly related to PD, such as α-synuclein
(α-syn) and DJ-1, or associated with neurodegeneration, such
as neurofilament light chain (NFL), tau, and β-amyloid 42
(Aβ42) have been investigated as potential biomarkers for
parkinsonism in CSF (reviewed in reference 4). Quantifica-
tion in serum of NFL, a protein involved in axonal growth and
regeneration,5 has recently been reported to have a high di-
agnostic value to differentiate APD from PD. Clearly, analysis
in serum is preferable to that in CSF.6
Our aim was to study the diagnostic value of serum NFL in
a unique cohort of patients with clear signs of parkinsonism, such
as bradykinesia with resting tremor or rigidity, but whose specific
diagnosis was uncertain at the time of collection of serum and
CSF, and who were followed for a maximum of 12 years.7 This
cohort is representative of the daily situation when clinicians are
confronted with a patient with an uncertain diagnosis, and where
biomarkers are needed most for an accurate diagnosis.
Methods
Classification of evidence
Our goal was to determine whether NFL levels in serum could
discriminate patients with APD (MSA and PSP) from patients
with PD, at a disease stage when the clinical diagnosis was still
uncertain. This study providesClass II evidence for the diagnostic
value of serum NFL to discriminate APD from PD and controls.
Patients and samples
We have selected patients with PD and APD from a pre-
viously described longitudinal study performed at the
Radboud University Medical Center (Nijmegen, the
Netherlands).7 Patients were consecutively recruited from
our movement disorders outpatient clinic between January
2003 and December 2006. All participants had clear signs
of parkinsonism, but based on clinical grounds, their spe-
cific diagnosis was uncertain at the time of inclusion. Exclusion
criteria were age younger than 18 years, history of brain surgery
or other neurodegenerative disease than parkinsonism, and
unstable comorbidity. All patients underwent a structured
interview, detailed and standardized neurologic examina-
tion, and, within 6 weeks after the initial visit, blood col-
lection and lumbar puncture among other ancillary
investigations (brain MRI, IBZM (iodobenzamide)-SPECT,
anal sphincter EMG). The study design, methods, and the
included patient populations have been extensively de-
scribed.7 After 3 years, the clinical condition was reevaluated
by a repeated structured interview and extensive neurologic
examination. Using the clinical findings at baseline and the
follow-up visit, a clinical diagnosis was established in con-
sensus by 2 movement disorder specialists according to the
existing clinical criteria by that time: the UK Brain Bank
criteria for PD,3 Gilman criteria for MSA,8 National Institute
of Neurological Disorders and Stroke and Society for Pro-
gressive Supranuclear Palsy criteria for PSP,9 Boeve criteria
for CBS,10 and Zijlmans criteria for vascular parkinsonism.
Twelve years after inclusion, 46 patients were reevaluated by
movement disorder specialists, and all clinical diagnoses
were evaluated again and updated according to most recent
clinical criteria11–14 and the most recent clinical information
regarding survival, response to L-dopa, evolution of symp-
toms, and neuropathologic confirmation whenever available,
were recorded. Diagnoses were determined by neurologists
who were blinded to the NFL levels in both serum and CSF.
Characteristics of patients are summarized in table 1.
Patients were selected for this study based on serum availability
and classified according to the most recent diagnosis after 12
years of follow-up, consisting of 55 patients with PD (classified
as possible n = 1, probable n = 38, clinically established n = 15,
definite n = 1), 22 patients with MSA (classified as possible
n = 4, probable n = 15, definite n = 3), and 7 patients with PSP
(classified as possible n = 3, probable n = 3, definite n = 1).
Patients with MSA and PSP were considered as one group
(APD) because of the low number of patients with PSP in this
study. An overview of patient inclusion and follow-up of clinical
diagnoses is shown in figure 1.
Clinical assessments were performed at baseline and after 3
and 12 years of follow-up, including disease severity and
cognitive function, by using the Hoehn and Yahr (H&Y)
scores,15 Unified Parkinson’s Disease Rating Scale,16 In-
ternational Cooperative Ataxia Rating Scale,17 Mini-Mental
State Examination (MMSE),18 and Scale for the Assessment
and Rating of Ataxia.19 A summary of clinical parameters from
all patients is available in table 2.
Glossary
Aβ42 = β-amyloid 42; α-syn = α-synuclein; APD = atypical parkinsonism disorder; AUC = area under the curve; CBS = cortical
basal syndrome;CI = confidence interval;H&Y =Hoehn and Yahr;MMSE =Mini-Mental State Examination;MSA = multiple
system atrophy; NFL = neurofilament light chain; PD = Parkinson disease; PSP = progressive supranuclear palsy; ROC =
receiver operating characteristic; Simoa = single molecule array.
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To investigate potential correlations of serum NFL with CSF
levels of NFL, α-syn, total tau, phosphorylated tau, DJ-1, Aβ42,
albumin, and serum albumin in patients with PD and APD, we
used previously collected data published by our group.7,20–22
Results of the biochemical analyses are summarized in table 1.
The nonneurologic controls consisted of a group of 53 patients
with suspicion of neurologic disorder who underwent serum and
CSF collection in the diagnostic workup of cognitive symptoms,
without evidence of dementia/Alzheimer disease (n = 16), di-
agnostic workup of neurologic symptoms without (somatic)
neurologic explanation (n = 11), to exclude neuroinflammatory
disease (n = 13) and subarachnoid hemorrhage (n = 10), or to
explain disturbances of intracranial pressure (n = 3). In none of
these control cases was a neurologic disease present, and leu-
kocyte count, glucose, total protein, blood pigments, lactate, and
(if assessed) oligoclonal immunoglobulin G bands were all
normal in their CSF. Characteristics of nonneurologic controls
are described in table 1.
Serum and CSF samples of PD, APD, and nonneurologic
controls were collected in polypropylene tubes, centrifuged,
aliquoted, and stored in polypropylene tubes at −80°C until
used for experiments.
Standard protocol approvals, registrations,
and patient consents
This study was approved by the ethical committee review
board Arnhem-Nijmegen (2002/188), and all participants
provided written informed consent.
Single molecule array
Serum NFL was measured with the single molecule array
(Simoa) NF-light Advantage Kit from Quanterix (Lexington,
MA). Serum samples were diluted 1:4 for the measurements
according to the manufacturer’s recommendation. Serum
quality-control samples with high- and low-endogenous NFL
concentration were included in all measurements (coefficient
of variation <5%). Serum NFL levels were determined by
researchers who were blinded to the clinical diagnosis.
Data analysis
The data analysis of this study was done by using SPSS Sta-
tistics 22 (IBM Corp., Armonk, NY) and GraphPad Prism 5
Table 1 Patient characteristics and biochemical measurements
Control PD MSA PSP p Valuea
No. 53 55 22 7
Sex, M/F 29/24 38/17 15/7 4/3 0.4
Age at inclusion, y 57.5 ± 9.8 57 ± 10 60.7 ± 7.1 68.9 ± 4.1 0.01b,c
Disease duration, mo NA 34.2 ± 26.3 33.9 ± 26.4 35.7 ± 19.2 0.8
Follow-up, y NA 10.3 ± 4.2 (n = 53) 3.9 ± 3.3 (n = 20) 4.7 ± 4.2 (n = 6) NA
Dopaminergic medication at
serum and CSF collection, no/yes
NA 44/11 15/7 4/3 NA
NFL in serum, ng/L 11.5 ± 6.5 10.4 ± 4.9 22.2 ± 11 25.6 ± 8.4 <0.0001b,c,d,e
NFL in CSF, ng/L 1,265 ± 551 (n = 32) 1,249 ± 666 (n = 54) 65,487 ± 4,138 (n = 21) 4,809 ± 4,064 (n = 7) <0.0001b,c,d,e
Ratio CSF/serum NFL 122.5 ± 44.9 269.4 ± 143.0 176.1 ± 106.3 <0.0001e
α-syn CSF, μg/L 26.4 ± 10 (n = 55) 28.4 ± 8.2 (n = 22) 33.7 ± 16.2 (n = 6) 0.4
Total tau, ng/L 213.2 ± 95.3 (n = 55) 275.2 ± 130.8 (n = 22) 266.6 ± 73.5 (n = 7) 0.03e
Phosphorylated tau, ng/L 49.1 ± 18.4 (n = 55) 46.1 ± 15.6 (n = 22) 53 ± 16.8 (n = 7) 0.6
DJ-1, ng/L 534.7 ± 128.2 (n = 29) 721.5 ± 242.5 (n = 15) ND 0.005e
Aβ42, ng/L 857.1 ± 206.6 (n = 55) 782.9 ± 199.6 (n = 22) 769 ± 156 (n = 7) 0.2
Ratio CSF/serum albumin 6.9 ± 3.0 7.0 ± 2.9 10.6 ± 7.0 0.3
Abbreviations: Aβ42 = β-amyloid 42; α-syn = α-synuclein; MSA = multiple system atrophy; n = number of samples; NA = not applicable; ND = not determined;
NFL = neurofilament light chain; PD = Parkinson disease; PSP = Progressive supranuclear palsy.
Values are expressed as mean ± SD.
a Parameterswere analyzedwith analysis of variance using Bonferroni as post hoc test in the case of gaussian distribution of data, Kruskal-Wallis withDunn as
post hoc test of nongaussian distribution for comparison of multiple groups, or Mann-Whitney U test for comparison of 2 groups. Sex was analyzed using χ2
test.
b Differences were found between control vs MSA.
c Differences were found between control vs PSP.
d Differences were found between PD vs PSP.
e Differences were found between PD vs MSA.
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(La Jolla, CA). Student t test, Mann-Whitney U test, analysis
of variance, followed by Bonferroni post hoc test, and Kruskal-
Wallis, followed by Dunn post hoc test, were used to assess
group differences. Sex was analyzed by χ2 test. Analysis of
covariance was done using age and sample storage time as
confounding factors. Correlations between 2 variables were
investigated by Spearman test, and partial correlation was
done using age as a covariate. To determine the diagnostic
accuracy, a receiver operating characteristic (ROC) curve was
constructed to determine the area under the curve (AUC) and
the values of sensitivity and specificity with 95% confidence
interval (CI), and Youden index was determined (sensitivity +
specificity − 1.0) to find the optimal cutoff value. Comparison
between ROC curves was done by using MedCalc software
trial version 18.2.1 (Ostend, Belgium). Risk estimation was
calculated yielding positive and negative predictive values and
by binary logistic regression to determine odds ratio by using
the cutoff of serum NFL concentration determined by the
optimal Youden index.
Data availability
Anonymized data will be shared on request from any qualified
investigator.
Results
We observed significantly higher NFL levels in serum of
patients with an APD compared to patients with PD and
nonneurologic controls (figure 2A). Group differences
remained highly significant after correction for age and sample
storage time (p < 0.0001). Serum NFL levels were similar for
patients with MSA and PSP (p = 0.4). Analysis of diagnostic
accuracy by construction of ROC curve yielded an AUC of
0.91 for discrimination of APD from PD (95% CI 0.83–0.98,
sensitivity = 86% and specificity = 85%, cutoff = 14.8 ng/L,
Youden index = 0.7) and an AUC of 0.88 to discriminate
patients with APD from controls (95% CI 0.80–0.96, sensi-
tivity = 93% and specificity = 71%, cutoff = 13.6 ng/L, Youden
index = 0.6) (figure 2B).
Risk estimation was calculated by using the cutoff value (14.8
ng/L) yielded by the optimal Youden index in the ROC
analysis (APD vs PD). Risk was estimated considering the
most recent clinical diagnosis (after 12 years of follow-up) in
our cohort. Among those patients who had serum NFL levels
above the cutoff value, the probability of having an APD is
76% (positive predictive value), and patients who had serum
NFL levels below the cutoff value have a 92% probability of
having PD (negative predictive value). In addition, analysis by
binary logistic regression yielded an odds ratio of 36 (95% CI
10.0–134.0), which means that patients with serum NFL
levels above the cutoff value have a 36-times-higher chance of
having APD over PD. Risk estimation values were retained
after taking age as covariate.
Serum NFL concentration correlated with age in both the
PD (r = 0.78, p < 0.0001) and control groups (r = 0.66,
p < 0.0001) but not in the APD group. Therefore, age was
used as a confounding factor for all further analyses de-
scribed below. Serum NFL was highly correlated with CSF
NFL levels in the 3 combined groups (r = 0.72, p < 0.0001)
(figure 3), as well as in the individual groups: PD, r = 0.34,
Figure 1 Inclusion and follow-up of patients included in this
study
Flowchart of follow-up of patients included in this study. (A) Patients with
uncertain diagnosis were included at baseline and part of the cohort was
evaluated again after 3 and 12 years for follow-up. Changes in the diagnosis
between the 3- and 12-year follow-up are indicated in italics. (B) Revision of
the diagnosis of all 156 cases after 12 years based on the current clinical
criteria and with all clinical information available at that time (even for
patients who were not available for follow-up after 3 or 12 years) and the
selection of the sample set for this study. APD = atypical parkinsonism dis-
order; MSA = multiple system atrophy; PD = Parkinson disease; PSP = pro-
gressive supranuclear palsy.
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p = 0.012; APD, r = 0.60, p < 0.001; controls, r = 0.39,
p = 0.029. Serum NFL levels in the combined cohorts, but
not in the individual groups, correlated with CSF DJ-1 (r =
0.47, p < 0.001). We observed a weak correlation between
the albumin CSF/serum ratio (a measure of blood-CSF
barrier integrity) and the NFL CSF/serum ratio (r = 0.24,
p = 0.04). No correlations were found between serum NFL
and CSF α-syn, Aβ42, total tau, or phosphorylated tau.
Serum NFL levels were associated with clinical parameters
only in the APD group. At baseline, serum NFL was cor-
related with the International Cooperative Ataxia Rating
Scale score (r = 0.60, p = 0.003) and tandem gait test
(r = 0.54, p = 0.004). At 3-year follow-up, serum NFL was
associated with tandem gait test (r = 0.53, p = 0.03), H&Y
score (r = 0.68, p < 0.001), MMSE (r = 0.60, p = 0.019),
and with the difference in H&Y scores measured at 3-year
follow-up and baseline (r = 0.69, p < 0.001). No correla-
tions between serum NFL and clinical parameters could be
determined at 12-year follow-up since only 2 patients with
APD were available for follow-up. Clinical parameters
were not determined in nonneurologic controls; therefore,
it was not possible to investigate any correlations in this
group.
Since our publication of CSF NFL concentrations in this
cohort,20 the diagnoses of the patients have been revised
resulting in a change in clinical diagnosis for 21 patients.
Therefore, we reanalyzed the previously published data
of NFL levels in CSF. NFL levels in CSF were higher
in APD (n = 32; 5,544 ± 4,137 ng/L) and discriminated
APD from PD (n = 65; 1,239 ± 638.1 ng/L, p < 0.0001) and
controls (n = 65; 1,348 ± 569.1 ng/L, p < 0.0001).
Diagnostic accuracy was as follows: APD vs PD, AUC =
0.90, 95% CI 0.82–0.95, sensitivity = 75% and specificity =
98%; APD vs controls, AUC = 0.89, 95% CI 0.81–0.94,
sensitivity = 75% and specificity = 100%. ROC curves for
the discrimination of APD from PD or controls using either
serum or CSF NFL were compared, but no significant
differences were found: PD vs APD, p = 0.94; controls vs
APD, p = 0.85.
Table 2 Clinical parameters of the parkinsonism cohort at baseline and 3- and 12-year follow-up
PD MSA PSP p Valuea
Baseline
H&Y score 2.0 ± 0.6 (n = 53) 2.4 ± 1.0 (n = 22) 3.3 ± 0.7 (n = 7) <0.0001b,c
UPDRS score 26.5 ± 11.9 (n = 52) 29 ± 13.9 (n = 21) 35.9 ± 15.6 (n = 7) 0.2
ICARS score 2.8 ± 3.0 (n = 50) 11.7 ± 11.7 (n = 18) 12 ± 7.4 (n = 5) <0.0001b,c
MMSE score 28.3 ± 2.1 (n = 54) 28 ± 2.2 (n = 21) 25.4 ± 2.8 (n = 7) 0.01c,d
Tandem gait 0.1 ± 0.3 (n = 54) 1.6 ± 1 (n = 21) 2.5 ± 0.5 (n = 7) <0.0001b,c
3-y follow-up
H&Y score 2.3 ± 0.7 (n = 52) 3.8 ± 1.4 (n = 17) 4.4 ± 0.5 (n = 5) <0.0001b,c
UPDRS score 28.8 ± 13.6 (n = 47) 32.5 ± 9.3 (n = 11) 41.6 ± 10.5 (n = 5) 0.03c
ICARS score 2.5 ± 2.2 (n = 43) 23.5 ± 19 (n = 10) 18 ± 9 (n = 5) <0.0001b,c
MMSE score 28.2 ± 2.2 (n = 44) 25.8 ± 2.8 (n = 11) 24.8 ± 4.4 (n = 5) <0.01b
Tandem gait 0.2 ± 0.7 (n = 49) 2.4 ± 1.1 (n = 14) 2.7 ± 0.6 (n = 3) <0.0001b,c
12-y follow-up
H&Y score 2.9 ± 0.8 (n = 29) n = 1 5 (n = 1) NA
UPDRS score 36 ± 14 (n = 22) ND 91 (n = 1) NA
SARA score 5.7 ± 2.2 (n = 29) 7.5 (n = 1) 20 (n = 1) NA
MMSE score 27.1 ± 4.7 (n = 30) 26 (n = 1) 22 (n = 1) NA
Tandem gait 1.4 ± 1.4 (n = 29) ND 4 (n = 1) NA
Abbreviations: H&Y = Hoehn and Yahr; ICARS = International Cooperative Ataxia Rating Scale; MMSE =Mini-Mental State Examination; MSA =Multiple System
Atrophy; n = number of samples; NA = not applicable; ND = not determined; PD = Parkinson Disease; PSP = progressive supranuclear palsy; SARA = Scale for
the Assessment and Rating of Ataxia; UPDRS = Unified Parkinson’s Disease Rating Scale.
Values are expressed as mean ± SD.
a Parameterswere analyzedwith analysis of variance using Bonferroni as post hoc test in the case of gaussian distribution of data, Kruskal-Wallis withDunn as
post hoc test of nongaussian distribution for comparison of multiple groups.
b Differences were found between PD and MSA.
c Differences were found between PD and PSP.
d Differences were found between MSA and PSP.
Neurology.org/N Neurology | Volume 92, Number 13 | March 26, 2019 e1483
Copyright © 2019 American Academy of Neurology. Unauthorized reproduction of this article is prohibited.
Discussion
In this study, we aimed to analyze whether NFL levels in serum
could be used as a biomarker for discrimination of APD from
PD and controls at a disease stage when the clinical diagnosis is
still uncertain. For this purpose, we measured NFL concen-
tration in the serum of patients with clear signs of parkinsonism
but with an uncertain diagnosis at the time of inclusion. Our
findings indicated that serum levels of NFL are significantly
increased in APDs vs PD or controls and discriminated APDs
from PD and controls with high accuracy levels. Furthermore,
high serum NFL levels were associated with a very high risk of
having an APD and low NFL levels were associated with a high
chance of having PD in our cohort.
NFL is one of the components of the axonal cytoskeleton,
thus release of NFL likely occurs after injury to axons with
subsequent release into interstitial fluid, which is drained to-
ward the CSF, and later to peripheral blood.23 Elevated NFL
levels in CSF have been described in various neurodegener-
ative disorders, such as Alzheimer disease,24 multiple
sclerosis,25,26 amyotrophic lateral sclerosis,24,27,28 fronto-
temporal dementia,29,30 Creutzfeldt-Jakob disease,31 Hun-
tington disease,32 PSP,33 CBS,4 and MSA.4 In parkinsonisms,
CSF NFL has been previously suggested as a biomarker for
discrimination of APD from PD (reviewed in reference 4).
Our findings of increased serumNFL in APDs are in line with
previous studies6,34,35 in which serum or plasma NFL levels
were studied in patients with PD and APD. The first study34
reported elevated NFL levels in the plasma of patients with
PSP compared to controls in 2 cohorts, and higher NFL
plasma levels were correlated with impairment of PSP
symptoms after a 1-year follow-up. We also observed positive
correlations of NFL levels and parameters of disease severity
in patients with APD with comparable age and cognitive
function (MMSE). The second study6 assessed NFL levels in
the serum of patients with PD and APD from 3 independent
cohorts. Two of these cohorts were characterized by inclusion
of patients with long disease duration (approximately 5 years)
with well-established diagnoses. The third cohort consisted of
patients with short disease duration up to 3 years. NFL levels
were higher in APDs in all 3 cohorts, with accuracy up to 91%
in the 2 cohorts with long-term follow-up and 81% in the
cohort with relative short follow-up. In comparison with this
latter cohort, we found even higher diagnostic accuracy
(91%). Our patients with PD and MSA were younger but had
similar disease severity compared to this published cohort
(based on H&Y score). The higher accuracy in our cohort is
probably attributable to a more accurate diagnosis after long-
term follow-up of our patients with repetitive clinical reas-
sessments of the diagnosis. The most recent study35 showed
higher serumNFL levels in patients with cerebellar-type MSA
compared to patients with sporadic adult-onset ataxia and
healthy controls. The NFL levels in those patients with MSA
were almost 3 times higher compared to our study. Although
Figure 2 Serum NFL highly discriminates APD from PD and
controls
Serum NFL concentration in patients with parkinsonism and diagnostic ac-
curacy. (A) Serum NFL levels are elevated in APD compared to PD and
nonneurologic controls. Data were analyzed using Kruskal-Wallis test and
Dunn as a post hoc test; mean levels are shown with SD; ***p < 0.0001. (B)
Receiver operating characteristic curves showed high accuracy levels for
discrimination of APD from PD (solid line) and APD from controls (dashed
line) by using NFL levels in serum. NFL levels were quantified by single
molecule array. APD = atypical parkinsonismdisorder; AUC = area under the
curve; NFL = neurofilament light chain; PD = Parkinson disease.
Figure 3NFL levels in serum are highly correlated with NFL
levels in CSF
Correlation analysis of NFL concentration measured in serum and in CSF.
NFL levels in serum and CSF were highly correlated in the combined par-
kinsonism and nonneurologic control groups. Spearman ρ coefficient value
and p value are indicated in the graph. NFL = neurofilament light chain.
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these patients had an age comparable to our patients at serum
withdrawal, their disease duration was longer, which may
explain the higher NFL levels.
Diagnostic accuracy is very similar for NFL in serum and in
CSF, as previously reported.6 Therefore, serum analysis could
replace CSF analysis for this goal, since blood collection is less
invasive and offers less discomfort for patients. Since NFL
concentrations are very low in serum, it was previously not
possible to detect its levels in serum by conventional methods,
such as ELISA. The recent development of Simoa technology
allowed researchers to assess very low NFL levels in serum.36
However, Simoa technology is an expensive technique,
whereas NFL levels in CSF could be quantified with cheaper
ELISAs. To reach even higher accuracy numbers, panels of
biomarkers, including NFL, have been proposed for dis-
crimination of APDs from PD and controls in CSF.37–39 In
the near future, such studies could include serum NFL to
further evaluate its diagnostic value for APD diagnosis.
Serum NFL levels correlated with age in PD and controls, but
not in the APD group. We could speculate that because NFL
levels are much higher in patients with APD this correlation
with aging is lost, although it might have existed earlier in the
disease process or even in a presymptomatic state. We did not
find associations between serum NFL levels and age in either
MSA or PSP group, which could be caused by the relative
small numbers of patients.
SerumNFL concentrations may be related to disease severity.
Although in a previous study no correlations between serum
NFL and clinical parameters were observed in the cohort with
relatively short follow-up,6 we observed several correlations
with clinical assessments in our APD cohort. This difference is
most likely explained by a more extensive clinical follow-up in
our study. Associations between NFL and clinical assessments
may suggest the use of NFL for monitoring or predicting
disease severity in APDs.
Elevated concentrations of NFL in body fluids are not specific
for one type of APD and may be a biomarker for general
axonal degeneration. Although NFL highly discriminated
APD from PD and controls, NFL levels cannot discriminate
among APDs, such as MSA and PSP in our cohort, which
could be caused by the small number of patients with PSP in
our study. Additional biomarkers may be needed, which may
aid clinicians to make a more detailed differentiation between
the various forms of APDs, such as misfolded forms of α-syn,
tau, and Aβ42.
39,40
A few limitations may apply to our study. First, our samples
were stored for an extended period of time at −80°C. Previous
studies assessed the effects of long-term storage of plasma and
CSF at −80°C.41,42 No effect of long-term storage effect was
found for several CSF proteins. However, for 18 plasma
proteins, concentrations may decrease or increase after long-
term storage, such as interleukin 13, interleukin 27, and
CD40. None of the studies reported on NFL. Therefore, we
assume that NFL concentrations remained the same in CSF
and serum after storage at −80°C. Moreover, sample storage
time did not affect our data analysis when it was taken as
a covariate. A second limitation of our study is that the final
diagnosis, which was used to determine diagnostic accuracy,
was only based on clinical evaluation and not yet confirmed
by neuropathologic examination. Although a team of
movement disorder specialists determined the clinical di-
agnoses according to international diagnostic criteria and
after long-term follow-up, which increased the chance of
correct classification, we cannot exclude that some patients
might have been incorrectly diagnosed. Third, we assessed
a high relative risk of having a diagnosis of APD when serum
NFL levels are elevated. However, these risk estimates are
only based on our population and thus require further
confirmation.
This study confirms the high diagnostic value of serum NFL
for discrimination of APD at early disease stages, offering
a great opportunity for further confirmation studies in larger
patient cohorts. Our findings suggest a possibility for differ-
entiation between PD and APD by serum rather than CSF
analysis. Serum NFL levels were associated with clinical
parameters of disease severity and cognitive decline, sug-
gesting that NFL might be used in the future for monitoring
or prediction of disease severity.
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